This inventor holds 2 USPTO granted patents and 4 published patent applications and 3 EPO patents. Top assignees: National Cancer Center, Sekisui Medical Co., Ltd.. Active years: 2016-2019.
Location History:
- Tokyo, JP (2016)
- Koto-ku, JP (2019)
Company Filing History:
2 out of 263 
1 out of 151 
Years Active: 2016-2019
Title: Yae Kanai: Innovator in Cancer Prognosis and Risk Assessment
Introduction
Yae Kanai is a notable inventor based in Koto-ku, Japan. He has made significant contributions to the field of cancer research, particularly in the prognosis and risk assessment of renal and hepatocellular carcinomas. With a total of 2 patents, his work aims to enhance the accuracy and efficiency of cancer diagnostics.
Latest Patents
Yae Kanai's latest patents include a method for determining the prognosis of renal cell carcinoma. This innovative approach provides a rapid, convenient, and highly accurate means of assessing the prognosis of patients with this type of cancer. The method involves treating genomic DNA from renal tissue with bisulfite, amplifying it through PCR, and analyzing the resulting product via ion exchange chromatography. The prognosis is determined based on the retention time of the detection signal obtained, with shorter times indicating a poor prognosis.
Another significant patent is a method for assessing the risk of hepatocellular carcinoma. This invention focuses on high sensitivity and specificity in evaluating the risk associated with this type of cancer. By analyzing 30 regions containing 45 CpG sites with differing DNA methylation levels, the method distinguishes between normal liver tissue and noncancerous liver tissue from patients with hepatocellular carcinoma. This allows for effective risk assessment based on established cutoff values.
Career Highlights
Throughout his career, Yae Kanai has worked with esteemed organizations such as the National Cancer Center and Sekisui Medical Co., Ltd. His experience in these institutions has contributed to his expertise in cancer research and diagnostics.
Collaborations
Yae Kanai has collaborated with notable colleagues, including Eri Arai and Yuriko Nemoto. Their combined efforts in research have further advanced the understanding of cancer prognosis and risk assessment.
Conclusion
Yae Kanai's innovative methods in cancer prognosis and risk assessment represent a significant advancement in medical diagnostics. His contributions are vital for improving patient outcomes in the fight against cancer.